The Cliniical Efficacy Of The Elderly Patients Of Myelodysplastic Syndrome, Treated With The Decitabine Combined With CAG Regimen

Objective To observe the clinic safety and efficacy of decitabine combined with CAG regimen in elderly patients of myelodysplastic syndrome(MDS). Method Totally 20 elderly patients with MDS treated with decitabine( 25mg/d d1-5 qd)combined with CAG regimen( ACR 10 mg/d d3-6 qd, Ara-C 10mgï¹’m-2ï¹’d-1 d3-9 q12 h, G-CSF 200ugï¹’m-2ï¹’d-1 d1-14 qd.We observed he clinic efficacy. Results 20 patients after the treatment to decitabine plus CAG,the remission rate(CR+mCR) was 50%, and the overall response rate(ORR, CR+mCR+PR+HI) was 90%. 1 year overall survival(OS) rate was 82%, 2 year OS rate was 58%, the average total survival time(14.15+11.21) months. Conclusions Treating the elderly patients of myelodysplastic syndrome with decitabine plus CAG,were having a higher rate of remission, less Non hematological adverse reactions, were well tolerated.